Why Oragenics, Inc.’ ONP-002 Phase IIa progress could redefine concussion treatment pathways
Can ONP-002 become the first approved concussion drug? Explore Oragenics’ Phase IIa progress and what it means for mTBI treatment.
Pharma & Biotech
Pharma & Biotech
Nasus Pharma Ltd. expands intranasal platform as NS002 moves closer to regulatory pathway
Nasus Pharma Ltd. advances NS002 toward pivotal trials with faster epinephrine delivery. Discover what this means for anaphylaxis care.
Pharma & Biotech
What SPONTAN reveals about Aptar’s nasal drug delivery platform and the race for rapid acting erectile dysfunction treatments
Aptar’s nasal drug delivery system enters Phase II trial for LTR Pharma’s SPONTAN erectile dysfunction therapy. Discover what this means for intranasal medicines.
Pharma & Biotech
Oragenics launches Phase IIa trial of ONP-002 as drug developers revisit traumatic brain injury therapies
Oragenics begins Phase IIa testing of ONP-002 for concussion. Discover how this trial could reshape drug development for traumatic brain injury.
Pharma & Biotech
Clearmind Medicine Inc. and Polyrizon Ltd. target formulation risk in MEAI’s addiction program
Discover how Clearmind Medicine Inc.’s intranasal MEAI strategy could reshape CNS drug delivery and clinical outcomes. Read the analysis.